Aim: The purpose of the study was to analyze disease-free survival in vulvar cancer patients in dependence of different factors. Methods: Disease-free survival in 203 patients with vulvar cancer was determined in dependence on the disease stage, depth of tumor invasion and method of treatment. There were 30 (14,7%) patients with stage I, 49 (24,13%) patients with stage II, 87 (42,85%) with stage III, 37 (18,22%) with stage IV.
Results: Relapses occurred in 18,29% patients with stage I, 20,5% with stage II, 26,68% with stage III, 46,25% with stage IV. Five-year disease-free survival was 46,7% in stage I, 22,4% in stage II, three-year survival was 2,5% in stage III, one-year survival in stage IV was 2,7%. The next significant factor was depth of tumor invasion. Patients with stage I and invasion up to 5 mm -five-year survival 50%, invasion over 5 mmtwo-year survival 2,4%. The same proportions were observed in patients with stage III: with invasion up to 5 mm -three-year survival 3,4%, invasion over 5 mm -one-year invasion 45,7%. When detecting disease-free survival in every stage in dependence on primary treatment, positive influence of chemotherapy in complex treatment was confirmed. In stage II patients under combined treatment disease-free five-year survival was 13,8%, with chemotherapy -35%; in stage III patients under combined treatment disease-free one-year survival was 40%, with chemotherapy -66,7%, two-year survival under complex treatment -17,8%, under combined -all patients without relapses died in less than two years. Conclusions: Thus, disease-free survival of patients depends on the disease stage, depth of tumor invasion and the treatment. Disclosure: All authors have declared no conflicts of interest.
